Evidence map›Paper›PMID 41781516›Full record

ArticleScientific reports2026

Pharmacophore-driven kinase profiling applied to the PKIS2 chemogenomic dataset.

Ronan Bureau, Jean-Luc Lamotte, Bertrand Cuissart, Alban Lepailleur

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ronan BureauCentre d'Etudes et de Recherche sur le Médicament de Normandie, Université de Caen Normandie, Normandie Univ, CERMN UR4258, UNICAEN, CERMN, Caen, 14000, France. ronan.bureau@unicaen.fr.
Jean-Luc LamotteGroupe de Recherche en Informatique, Image, Automatique et Instrumentation de Caen, Normandie Univ, ENSICAEN, CNRS, UNICAEN, GREYC UMR 6072, Caen, 14000, France.
Bertrand CuissartGroupe de Recherche en Informatique, Image, Automatique et Instrumentation de Caen, Normandie Univ, ENSICAEN, CNRS, UNICAEN, GREYC UMR 6072, Caen, 14000, France.
Alban LepailleurCentre d'Etudes et de Recherche sur le Médicament de Normandie, Université de Caen Normandie, Normandie Univ, CERMN UR4258, UNICAEN, CERMN, Caen, 14000, France.

Funding

Agence Nationale de la Recherche ANR-20-CE-23-0023
6 · The paper itself

Abstract

We present a data-driven and unsupervised approach for extracting 3D pharmacophore hypotheses, without prior ligand selection, from a chemogenomic kinase dataset (406 kinases and 645 compounds, PKIS2). A metric called NEM for Normalized Enrichment Measure is introduced for each pharmacophore, which quantifies change in the proportion of active compounds consistent with the pharmacophore compared to the original dataset. Based on this metric, we can identify pharmacophores associated with specific kinases and, conversely, determine all kinases that share similar metric values. This approach enables the characterization of polypharmacological profiles linked to individual pharmacophore hypotheses. We further evaluate the consistency of our results with various biological datasets, including ChEMBL, DrugBank, LINCS, KINOMEscan, and Kinobeads, showing agreement across representative case studies. This study highlights the potential of our approach for elucidating relationships between pharmacophores and kinase selectivity profiles, providing a scalable framework for exploring kinase–ligand interaction landscapes.

Indexed as

Protein Kinase InhibitorsProtein KinasesHumansLigandsPharmacophoreLigandsProtein Kinase InhibitorsProtein KinasesCheminformaticsIsomorphismKinase inhibitorsPattern miningPharmacophoresPolypharmacology

Identifiers

PMID41781516
PMCPMC13076861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.